Through the acquisition, Infosys will get domain experts with commercial, digital marketing, medical, clinical, regulatory, and quality expertise
Infosys to acquire BASE life science. (Credit: Sundar/Wikimedia Commons)
Infosys has agreed to acquire BASE life science, a Danish technology and consulting firm in the life sciences industry in Europe, for a price of up to €110m.
The acquisition will be carried out by the Indian IT firm’s fully-owned subsidiary Infosys Consulting and the consideration to be paid will cover management incentives, bonuses, and retention.
Founded in 2007, BASE life science is said to have nearly 200 life science domain experts.
It provides business consulting and technology services to global life sciences firms. The company helps its clients in realising business value from data and cloud-first digital platforms apart from helping them in fast tracking clinical trials and scaling drug development.
BASE life science’s multidisciplinary industry experts are located across Denmark, Switzerland, the UK, Italy, Germany, and France. The technology and consulting firm has a nearshore technology hub in Spain as well.
It collaborates with Veeva, IQVIA, Salesforce and other software technology providers in the life sciences industry.
Under the ownership of Infosys, BASE life science is expected to further expand its portfolio of expertise into consumer health, animal health, MedTech, and genomics segments.
BASE life science CEO Martin Woergaard said: “Over the last five years, BASE life science has delivered tremendous growth, and created a stellar life sciences consulting firm in Europe. With Infosys as our catalyst, we will be able to accelerate our expansion internationally and create development opportunities for our people.
“Infosys is a solid, global technology leader, that is a perfect match for ensuring continuous success of BASE while sharing our common purpose and values.”
Infosys said that the acquisition of BASE life science brings domain experts with commercial, digital marketing, medical, clinical, regulatory, and quality expertise.
The Danish firm is claimed to strongly focus on data and artificial intelligence (AI), and has the ability to bridge and integrate business logic and technology for driving insights to help with enhanced health outcomes.
Infosys president Ravi Kumar S said: “This acquisition augments Infosys’ deep life sciences expertise, and expands our footprint further in the Nordics region and across Europe, and scales our digital transformation capabilities with cloud-based industry solutions.
“We are excited to welcome BASE life science and its leadership team into the Infosys family.”
The transaction is subject to customary closing conditions and is expected to be wrapped up in the second quarter of fiscal 2023.